Grupo para la caracterización molecular de las neoplasias hematológicas
Pfizer (United States)
Nueva York, Estados UnidosPublications in collaboration with researchers from Pfizer (United States) (1)
2023
-
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nature Medicine, Vol. 29, Núm. 9, pp. 2259-2267